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There are currently an estimated 320 000 children aged <15 years 
living with HIV in South Africa (SA).[1] Owing to a combination of 
recent success in preventing new vertical HIV infections and success 
of paediatric combination antiretroviral therapy (ART) programmes 
in improving life expectancy in perinatally HIV-infected (PHIV) 
children, the burden of paediatric HIV in SA has changed to older 
children, and this effect is projected to increase further by 2020.[2] 
There is an increasing population of PHIV children on ART reaching 
adolescence in SA’s healthcare system, yet information on long-term 
treatment outcomes in this unique group of highly treatment-
experienced adolescents is very limited. Adolescence in general is 
a period characterised by physical, emotional and psychological 
change. It is associated with developing autonomy and sexuality, 
questioning authority, greater peer influence, increased impulsivity 
and risk taking.[3] Adolescents with HIV may be at high risk of poor 
ART adherence, drug resistance and viral failure (VF).[4,5] Barriers to 
adherence can include busy schedules (school and social), treatment 
fatigue, high pill burdens, complex twice-daily regimens, drug side-
effects and disclosure issues.[3] In addition, socioeconomic difficulties 
related to orphanhood and stigma, as well as HIV-related behavioural 
and neurocognitive consequences, can adversely affect adolescent 
adherence.[6]
Many PHIV children are reaching adolescence and beyond, 
transitioning to adult care, yet healthcare systems are often lacking 
in preparedness to deal with the complex and evolving needs of these 
children as they age into adolescence and young adulthood. In Africa, 
HIV services dedicated to young people and their needs are scarce[7] 
and when VF occurs, there are limited second- and third-line ART 
options available, particularly when protease inhibitors (PIs) have 
been used in the first-line regimen in children. While several studies 
have reported on viral and immunological outcomes in PHIV cohorts 
on ART, few have reported the outcomes after more than a decade of 
treatment. Viral suppression ranged from 37% to 68% and optimal 
immune status (CD4+ count >500 cells/µL) from 42% to 59% in 
these studies, which were all from high-income countries in Europe 
and North America.[8-13] Cohort size ranged from 112 to 654 patients, 
median duration of follow-up was 11 - 16 years and median age at 
analysis was 12 - 19 years. These studies may not be generalisable to 
low- and middle-income countries (LMICs), including SA, as on the 
one hand many children in these cohorts were exposed to older, less 
efficacious regimens in the 1990s, while on the other hand they were 
likely to have had access to a wider range of antiretrovirals and more 
tailor-made regimens than children in LMICs in the 2000s.
Objectives
There are no published data on outcomes in PHIV children in 
LMICs on ART for ≥10 years. Although national paediatric ART 
programmes were implemented in SA over a decade ago, the long-
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experiencing viral failure (VF) was 56.7% (95% confidence interval (CI) 48.3 - 65.5) and the 10-year probability of switching to second-line 
ART 45.7% (95% CI 37.5 - 54.8). The probability of experiencing VF between the ages of 10 and 18 years was 37.4% (95% CI 25.4 - 52.8).
Conclusions. Virological and immunological outcomes were good overall in PHIV children who remained in care for ≥10 years at this 
clinic, but >40% of children were on second-line ART with poorer immunological outcomes.
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term outcomes of PHIV children on ART have not yet been described. 
This study aimed to contribute to available knowledge by describing 
local outcomes that can aid in anticipating future challenges and 
planning further management in treatment-experienced adolescents 
and young adults. The main objective was to describe long-term 
clinical, growth, immunological and virological outcomes in PHIV 
children on ART.
Methods
We conducted a retrospective cohort study of PHIV adolescents 
on ART. Primary outcomes were annual viral load (VL) and CD4+ 
results. Secondary outcomes were ART regimen history, resistance 
test results, height and weight measurements, history of opportunistic 
infections and hospital admissions. The study population consisted 
of PHIV adolescents and young adults attending the Adolescent 
Infectious Diseases Clinic at Groote Schuur Hospital (GSH) in 
Cape Town, SA. This is a tertiary-level clinic in an urban setting. 
The paediatric ART programme was initially implemented in 2002 
by a non-governmental organisation (Kidzpositive), and was taken 
over by the provincial Department of Health during 2004. Initially 
the clinic managed only paediatric cases referred from primary/
secondary facilities; later it evolved to form a dedicated PHIV 
adolescent service with access to support from psychologists, social 
workers, counsellors and peer support groups. Approval for the 
research was obtained from the University of Cape Town’s Faculty 
of Health Sciences Human Research Ethics Committee (ref. no. 
891/2015).
Participants were identified from the clinic’s enrolment register 
and attendance database. Inclusion criteria were: (i) ART initiation 
at the GSH paediatric clinic or in the GSH paediatric ward (with 
follow-up at the clinic); (ii) age <12 years at initiation (maximum 
age for referral to paediatric services; also serves as a proxy for 
perinatal route of infection); (iii) ART initiation between 13 May 
2002 (inception of the ART programme) and 31 December 2005; 
(iv) attendance at the clinic for a minimum of 10 years since ART 
initiation date, including those who had previous gaps in care or had 
been transferred out but returned and were in care ≥10 years after 
ART start; (v) previously ART naïve, with the exception of possible 
nevirapine exposure as part of the prevention of mother-to-child 
transmission programme implemented in the Western Cape Province 
from 1999; and (vi) children who initiated care at the clinic as part of 
a clinical research study were included, provided that the study was 
a pharmacokinetic one and not a study comparing the effectiveness 
of different antiretroviral treatments or other interventions. We 
excluded those who were not in care at the clinic for at least 10 years 
after ART initiation due to death, loss to follow-up (LTFU) or transfer 
of care to another institution. Clinical data were collected from the 
patients’ clinical records. Tuberculosis diagnoses and reasons for 
hospital admission were based on physician assessment and therefore 
may not always have been based on laboratory results. CD4+ and 
VL results were obtained from the National Health Laboratory 
Service. Information was captured from the time of ART initiation 
until the censoring date when LTFU, death or transfer occurred or 
until the study ended on 31 December 2015 if the patient was still 
in active care. Data were compiled into Excel spreadsheets version 
2013 (Microsoft, USA) and uploaded to Stata version 14 (StataCorp, 
USA) for analysis. The Z-test was used for comparing differences 
in proportions. Medians and interquartile ranges (IQRs) were used 
to describe data that were not normally distributed. Kaplan-Meier 
survival analysis and Cox proportional hazard methods of analysis 
were applied to identify time to VF and factors associated with 
VF. Independent variables for inclusion in multivariable models 
were selected a priori. Based on existing literature, age, gender, 
programme year, baseline CD4+ count and VL, drug regimen and 
drug formulation were selected as potentially having associations 
with probability of VF. We examined the effect of age on VF in 
different ways by including age in different models as current age, 
current age category, age at ART start and age category at ART start.
Viral suppression was regarded as a VL <400 copies/mL. VF was 
regarded as two sequential VLs >1 000 copies/mL at >24 weeks 
since ART initiation, taken between 14 and 365 days apart and not 
measured during a treatment interruption. Annual CD4+ and VL 
were defined as the measure taken nearest to but within ±6 months 
of the respective annual time points. The World Health Organization 
(WHO) age-related classification of immunosuppression was used.[14] 
Optimal immune status was defined as age ≤11 months and CD4+ 
>35%, age 12 - 35 months and CD4+ >30%, age 36 - 59 months 
and CD4+ >25%, and age ≥5 years and CD4+ count >500 cells/µL. 
Changing from first- to second-line therapy was defined as changing 
at least two antiretroviral drugs in the regimen, one of which was a 
class switch from a non-nucleoside reverse transcriptase inhibitor 
(NNRTI) to a PI or from a PI to an NNRTI, where the reason for 
changing drugs was VF and not toxicity and the child was not virally 
suppressed at the time of the switch. Genotypic drug resistance was 
defined as intermediate- or high-level resistance. LTFU was defined 
as no visit for >6 months before database closure in a child not known 
to have transferred out or died, provided that the child had at least 
10 years of follow-up since the start of ART. Children with <10 years 
of follow-up were excluded from the study. WHO child growth 
reference values were used to calculate anthropometric z-scores.[15] 
Weight-for-age z-scores were not calculated after 10 years of age as 
there are no WHO reference values for this age group.
Results
Cohort characteristics
Between May 2002 and December 2005, 349 children enrolled for 
ART initiation. Before reaching 10 years of follow-up, 29 (8.3%) 
died, 33 (9.5%) were LTFU, 150 (43.0%) were transferred to other 
facilities (with no transfer back to GSH) and 10 (2.9%) had missing 
records. The remaining 127 (36.4%) were in care for ≥10 years and 
formed the study cohort. At ART initiation, the median age of the 
127 children included in the study was 31 months (IQR 16 - 58) and 
the median CD4+ percentage was 13.0% (IQR 8.9 – 18.0), with 62.8% 
of the children classified as severely immunosuppressed. Of the 
children, 12 (9.4%) started ART as inpatients. Children were followed 
up for a median of 12.2 years (IQR 11.1 - 12.9), with a mean of six 
clinic visits per year. Among the cohort of 127 children, 26 (20.5%) 
transferred to other facilities for care and subsequently transferred 
back again, mainly for adolescent support. During the study period 
following 10 years since ART initiation, among the cohort of 127 
children, 1 patient died, 2 were LTFU and 19 (15.0%) transferred to 
other clinics. Participants’ ages ranged from 10 to 22 years at study 
close. Characteristics of the children at ART initiation and at the last 
assessment are shown in Table 1.
Treatment history
At ART initiation, 63.8% of children were on NNRTI-based and 
36.2% on PI-based regimens (Table 1). Over time, there were 91 
instances of documented patient- or caregiver-initiated treatment 
interruptions, which occurred in 40 patients (31.5%). Drug switches 
due to lipodystrophy were made in the regimens of 64 patients 
(50.4%) at a median age of 11 years, mostly attributable to stavudine 
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Table 1. Characteristics of 127 children* at ART start and at last assessment
Characteristic At ART start At last assessment
Sex, n (%)
Male 62 (48.8)
Female 65 (51.2)
Age (years), median (IQR) 2.6 (1.3 - 4.9) 15.1 (13 - 17.7)
Age category (years), n (%)
<1 23 (18.1)
1 - 4 73 (57.5)
5 - 9 26 (20.5)
10 - 14 5 (3.9) 60 (47.2)
≥15 67 (52.8)
Year of ART start, n (%)
2002 33 (26.0)
2003 52 (40.9)
2004 23 (18.1)
2005 19 (15.0)
Previous exposure to PMTCT, n (%)
Known exposed 9 (7.1)
Known unexposed 32 (25.2)
Unknown 86 (67.7)
CD4% by age category (years), median (IQR)
<1 9.7 (6.9 - 17.0) (n=22)
1 - 4 14.4 (10.0 - 18.0) (n=68)
CD4+ count (cells/µL) by age category (years), median (IQR)
5 - 9 350 (210 - 537) (n=26)
10 - 14 292 (173 - 353) (n=5) 846 (654 - 1 019) (n=60)
≥15 653 (479 - 719) (n=67)
Immune suppression category†, n (%)
None 13/121 (10.7) 100 (78.7)
Mild 8/121 (6.6) 12 (9.4)
Advanced 24/121 (19.8) 10 (7.9)
Severe 76/121 (62.8) 5 (3.9)
VL (copies/mL), n (%)
>1 million 14/80 (17.5) 0 (0)
<400 1/80 (0.8) 101 (79.5)
WAZ, overall, median (IQR) –1.97 (–3.23 - –0.66) (n=115) n/a‡
WAZ category, n (%)
≥–2 58/115 (50.4)
<–2 57/115 (49.6)
HAZ, overall, median (IQR) (n=113) –2.92 (–4.09 - –1.95) –1.52 (–2.22 - –0.79)
HAZ category, n (%)
≥–2 31/113 (27.4) 87 (68.5)
<–2 82/113 (72.6) 40 (31.5)
BAZ, overall, median (IQR) (n=113 at ART start) 0.2 (–0.78 - 1.25) –0.16 (–1.04 - 0.56)
BAZ category, n (%)
≥–2 98/113 (86.7) 120 (94.5)
<–2 15/113 (13.3) 7 (5.5)
c-ART regimen, n (%)
NVP + 2 NRTIs 78 (61.4) 12/120 (10.0)
LPV/RTV + 2 NRTIs 34 (26.8) 63/120 (52.5)
RTV + 2 NRTIs 12 (9.4) -
EFV + 2 NRTIs 3 (2.4) 21/120 (17.5)
ATAZ/RTV + 2 NRTIs - 17/120 (14.2)
Other - 7/120 (5.8)
ART = antiretroviral therapy; IQR = interquartile range; PMTCT = prevention of mother-to-child transmission of HIV; VL = viral load; WAZ = weight-for-age z-score;  
HAZ = height-for-age z-score, BAZ = body mass index-for-age z-score; c-ART = combination ART; NVP = nevirapine; NRTI = nucleoside reverse transcriptase inhibitor; LPV = lopinavir;  
RTV = ritonavir; EFV = efavirenz; ATAZ = atazanavir.
*All 127 children were included unless n is specified.
†Immunodeficiency categories: None if ≤11 months and CD4+ >35%, 12 - 35 months and CD4+ >30%, 36 - 59 months and CD4+ >25%, ≥5 years and CD4+ count >500 cells/µL;  
mild if ≤11 months and CD4+ 30 - 35%, 12 - 35 months and CD4+ 25 - 30%, 36 - 59 months and CD4+ 20 - 25%, ≥5 years and CD4+ count 350 - 499 cells/µL; advanced if ≤11 months and 
CD4+ 25 - 29%, 12 - 35 months and CD4+ 20 - 24%, 36 - 59 months and CD4+ 15 - 19%, ≥5 years and CD4+ count 200 - 349 cells/µL; severe if ≤11 months and CD4+ <25%, 12 - 35 months  
and CD4+ <20%, 36 - 59 months and CD4+ <15%, ≥5 years and CD4+ <15% or CD4+ count <200 cells/µL.
‡Not applicable, because WAZ is not calculated after the age of 10 years using World Health Organization reference values.
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but also to zidovudine and didanosine. At 
the last assessment, 49.6% of patients were 
on first-line ART, 43.3% on second-line ART, 
3.1% on salvage therapy or monotherapy, 
and 3.9% on no ART. Among those on 
combination ART, 27.5% were on NNRTI-
based and 71.7% on PI-based regimens. One 
patient was using an integrase inhibitor.
Virological outcomes
After ART initiation, 75.6% of children 
initially had viral suppression and 41.7% 
maintained good virological control, never 
experiencing VF throughout follow-up 
(Fig.  1). Two children never experienced 
viral suppression throughout follow-up.
The Kaplan-Meier probability of experi-
encing VF by 10 years after ART initiation 
was 56.7% (95% confidence interval 
(CI) 48.3 - 65.5). Among those who experi-
enced VF (74/127, 58.3%), VF occur red at 
a median age of 4.0 years (IQR  2.9  - 8.3) 
and a median duration on ART of 1.5 years 
(IQR 1.1 - 2.6). The 10-year probability of 
switching to second-line ART was 45.7% 
(95% CI 37.5 - 54.8). Factors associated with 
a first episode of VF were analysed by Cox 
proportional hazards modelling (Table 2, A). 
Female sex was independently associated 
N=127 started 
ART
n=96 
suppressed
n=74 
had rst VF
Median age 4 years
n=68 
re-suppressed
n=27 
had second VF
Median age 10 years
n=23 
re-suppressed
n=7 
had third VF
Median age 13 years
n=5 
re-suppressed
n=1 
had fourth VF
Age 15 years
n=1 
re-suppressed
n=6 stayed in VF
n=53 had no subsequent VF
n=41 had no subsequent VF
n=16 had no subsequent VF
n=4 had no subsequent VFn=2 stayed in VF
n=4 stayed in VF
Fig. 1. Flow diagram of cohort progression to viral suppression and VF after ART initiation. (ART = 
antiretroviral therapy; VF = viral failure.)
Table 2. Factors associated with (A) first episode of VF and (B) VF after age 10 years, from multivariate Cox modelling
Adjusted HR 95% CI p-value
A. Factors associated with first VF
Sex
Male 1
Female 0.46 0.24 - 0.87 0.017
Type of regimen
NNRTI-based 1
PI-based 0.47 0.14 - 1.61 0.228
Age at ART start (years) 1.07 0.91 - 1.26 0.399
Programme year
2002 1
2003 0.90 0.43 - 1.90 0.777
2004 1.25 0.23 - 6.64 0.797
2005 0.33 0.07 - 1.66 0.180
Severe immune suppression at ART start 1.52 0.67 - 3.42 0.315
VL >1 million copies/mL at ART start 1.48 0.64 - 3.44 0.365
Drug formulations
Tablets only 1
Use of suspensions 3.78 1.24 - 11.54 0.020
B. Factors associated with VF after age 10*
Sex
Male 1
Female 1.44 0.64 - 3.24 0.378
Type of regimen
NNRTI-based 1
PI-based 0.75 0.25 - 2.27 0.612
Age at ART start (years) 1.11 0.93 - 1.32 0.232
Programme year
2002 1
2003 1.52 0.54 - 4.25 0.428
2004 1.51 0.37 - 6.07 0.563
2005 2.20 0.41 - 11.98 0.360
Previous VF <10 years old 3.20 1.05 - 9.75 0.040
CD4+ <350 cells/µL at age 10 4.05 1.04 - 15.82 0.044
VF = viral failure; HR = hazard ratio; CI = confidence interval; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; ART = antiretroviral therapy; VL = viral load.
*10 children with VF at age 10 were excluded from analysis.
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with a 0.46 times lower hazard of developing 
VF (95% CI 0.24 - 0.87). Use of suspensions 
in the ART regimen compared with use 
of tablets only was associated with a 3.78 
times increased hazard of VF (95% CI 1.24 - 
11.54). In sensitivity analyses where age was 
included in the model in different ways, the 
association between use of suspensions and 
VF was similar and remained significant.
At the last assessment, 79.5% of the cohort 
were virally suppressed (86.2% on first-line 
ART v. 76.8% on second-line ART; p=0.183). 
There was no significant difference in the 
proportion virally suppressed on NNRTI-
based v. PI-based regimens (88.6% v. 77.8%; 
p=0.169), by age 10 - 14 v. ≥15 years at 
last assessment (83.3% v. 74.5%; p=0.224), 
or by history of previous exposure to 
single-PI ritonavir v. not (72.2% v. 80.8%; 
p=0.41). The Kaplan-Meier probability of 
experiencing VF between the ages of 10 
and 18 years was 37.4% (95% CI 25.4 - 
52.8). VF occurred at a constant probability 
throughout adolescence (Fig. 2). Advanced 
immunodeficiency (CD4+ count <350 cells/
µL) at age 10 years was independently 
associated with a 4.05 times increased hazard 
of developing VF during adolescence (95% 
CI 1.04 - 15.82) (Table 2, B). In addition, 
having a history of previous VF before the 
age of 10 was independently associated with 
a 3.20 times increased hazard of developing 
VF after the age of 10 years (95% CI 1.05 - 
9.74). The proportion of patients virally 
suppressed at each year since ART initiation 
increased gradually until 8 years after ART 
initiation and decreased thereafter (Fig. 3).
Ten percent of the cohort had drug 
resistance documented, which was found in 
13 of the 16 children tested. Of these, 2 had 
nucleoside reverse transcriptase inhibitor 
(NRTI) resistance, 2 had NNRTI resistance, 
7 had both NNRTI and NRTI resistance and 
2 had both PI and NRTI resistance.
Immunological outcomes
At the last assessment, the median CD4+ 
count was 686 cells/µL (IQR 545 - 859), 3.9% 
of the cohort had a CD4+ count <200 cells/
µL, and 78.7% had a CD4+ count >500 cells/
µL (Table 1). Patients on first-line ART at 
last assessment were more likely than those 
on second-line ART to have a CD4+ count 
>500 cells/µL (92.1% v. 70.9%; p=0.003). 
Similarly, those on NNRTI-based regimens 
were more likely than those on PI-based 
regimens to have a CD4+ count >500 cells/
µL (93.9% v. 76.7%; p=0.030). Stratified by 
age 10 - 14 v. age ≥15 years at last assessment, 
91.7% v. 61.8% (p<0.001) had a CD4+ count 
>500  cells/µL. The percentage of patients 
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Figure 2A: Kaplan Meier probability of (i) viral failure by age 10 years and (ii) new 
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with optimal immunological status at each 
year after ART initiation showed increases 
until 7 years and decreased thereafter 
(Fig. 4).
Growth
At the last assessment, 5.5% of children were 
wasted (body mass index for age z-score 
<–2), compared with 13.3% at ART initiation. 
At ART initiation, median height-for-age 
z-score (HAZ) was –2.92 (IQR –4.09 - –1.95) 
and 72.6% of the children were stunted 
(HAZ <–2) (Table 1). At the last assessment, 
median HAZ was –1.52 (IQR –2.22 - –0.79) 
and 31.5% were stunted. Although the HAZ 
improved over time, it remained below 
WHO child growth reference values (Fig. 5).
Clinical outcomes
The number of hospital admissions was 
highest in the first year after ART initiation, 
and decreased thereafter (Table 3, A). 
Across the entire follow-up period, the 
most common reasons for admissions were 
lower respiratory tract infections (45.7%) 
and pulmonary tuberculosis (9.5%). The 
incidence of tuberculosis was high: across 
the entire follow-up period, 68 episodes of 
tuberculosis were diagnosed in 58 patients 
(45.7% of the cohort); 53 of these episodes 
occurred in 51 patients (40.2% of the cohort) 
>4 weeks after ART initiation (Table 3, B). 
Among those who developed tuberculosis 
>24 weeks after ART initiation, 55.1% 
were not virally suppressed at tuberculosis 
diagnosis. Chronic lung disease was 
documented in 33 (26.0%) of the cohort.
Discussion
To our knowledge, this is the first published 
study of outcomes of PHIV children in 
SA after >10 years in HIV care, albeit 
from a single centre. After median follow-
up of 12 years on ART, 79.5% of this 
cohort were virally suppressed and 78.7% 
had optimal immune status. These results 
compare favourably with studies in high-
income countries.[8-13] However, these PHIV 
adolescents comprise a vulnerable group, 
with impaired growth outcomes and ongoing 
burden of clinical disease. Maintaining 
virological control and optimal immune 
status in adolescence may be challenging. A 
high proportion of patients have already had 
at least one episode of confirmed VF before 
adolescence, and approximately one in three 
experience new confirmed VF between the 
ages of 10 and 18 years.
Both immunological and virological 
outcomes initially improved substantially 
after ART initiation in this group, but 
appeared to deteriorate about 10 years after 
the start of ART. Understanding the reason 
for these deteriorating outcomes is crucial 
to developing targeted interventions to 
address them. In this respect, VF occurred 
at a constant rate after age 10 years, similar 
to results in Asian adolescents.[16] Entering 
adolescence with a CD4+ count <350 cells/
µL or with a history of previous VF were 
predictors of experiencing new VF during 
adolescence. In addition, it was notable 
that adolescents aged >15 years, those on 
second-line therapy and those on PI-based 
therapy were more likely to have CD4+ 
counts <500 cells/µL.
Across the entire follow-up period, we 
found an increased hazard of VF in children 
using suspensions. Because younger children 
are more likely to be prescribed suspensions 
than tablets, we conducted sensitivity analysis 
to examine the association of suspension use 
with VF more closely. Sensitivity analysis 
with current age and age at ART start as both 
numerical and age categories (<5 v. ≥5 years) 
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showed a statistically significant association, with similar effect size, 
of suspension use with VF. Although the effect was robust to different 
ways of adjusting for age, we cannot conclusively say the association 
is causal. Nevertheless, it is not surprising, as some suspensions are 
unpalatable, giving accurate doses is more difficult compared with 
tablets, especially if a child vomits or spits out the medicine, and 
frequent weight-based dosage changes are needed as the child grows, 
with risk of errors (by clinicians or caregivers). Optimising drug 
formulations across the paediatric age range may reduce the risk 
of VF and drug resistance, facilitating better adolescent outcomes. 
Resistance testing is not routinely performed in SA when changing 
from an NNRTI-based regimen due to VF, nor is it routinely 
performed when VF occurs in patients on a PI-based regimen if 
ongoing poor adherence is observed. The true incidence of resistance 
is therefore likely to be higher than the 10% documented.
The high burden of stunting, hospitalisation and clinical disease, 
especially tuberculosis, despite several years on ART in our cohort, 
is notable. The majority of incident tuberculosis cases occurred in 
patients who were not virally suppressed. This is consistent with 
findings in adult studies that HIV-infected patients with a high VL 
are at high risk of tuberculosis, irrespective of CD4+ counts.[17,18] One 
in four children in our cohort had chronic lung disease, a well-known 
complication among PHIV adolescents, particularly in sub-Saharan 
Africa.[19,20] Despite HAZ improvements in childhood, in this study 
and others in LMICs[21,22] PHIV adolescents continue to be at least 
one standard deviation below normal height, with potential impact 
on final adult height.
Study strengths and limitations
This is one of the first studies with >10 years of follow-up of PHIV 
adolescents from sub-Saharan Africa. Strengths of our study include 
the detailed long-term individual trajectories, including VL and 
clinical outcomes, and that the study reflects the real world rather 
than trial settings. The extended time frame allowed for inclusion of 
patients who had previous gaps in care or transfer out and who at 
an earlier stage would have been considered LTFU or transferred to 
another site. Limitations of the study include the small sample size, the 
retrospective study design, and that the data come from a single study 
site in a tertiary care institution. Since we focused on children who 
had been on ART for at least 10 years at the same site, there is survival 
bias in this cohort. Nevertheless, it is precisely this surviving group 
of PHIV adolescents that needs to be described in order to optimise 
management during adolescence and transition to adulthood.
There may be reduced external validity owing to this being a 
tertiary care cohort. In SA and sub-Saharan Africa more broadly, the 
model of retaining children at a separate paediatric tertiary facility 
is unusual. In addition, there is selection bias in the current cohort 
of children with ≥10 years of follow-up, as many were long-term 
survivors and regular clinic attendees during the era before ART was 
widely available. Subsequent cohorts of adolescents will have had the 
advantage of starting ART before the onset of severe disease. The 
children in this study benefited from tertiary-level support available 
at the clinic, so results from the study may not be generalisable to 
children treated at primary care level where HIV services dedicated 
to young people and their needs are often lacking. Some variables that 
may be related to the risk of developing VF, for example adherence 
to ART, caregiver factors, disclosure, depression and neurocognitive 
deficits, were not explored in this study. Sample size was not 
calculated to detect any differences between groups.
Conclusions
Long-term virological and immunological outcomes were good 
overall in PHIV children remaining in care for ≥10 years. However, 
a worsening trend was observed in adolescence, which may reflect 
growing autonomy and worse adherence during adolescence. 
Given their long-term treatment histories, including prior VF and 
ongoing clinical disease burden, these adolescents will require careful 
management as they transition to adult care and beyond. There is a 
need for similar studies of long-term outcomes in PHIV children 
at other sites in SA, particularly in primary care settings, as well as 
further studies of PHIV individuals after they have transitioned to 
adult care.
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Table 3. Clinical outcomes of 127 children on ART: (A) hospital admissions and (B) tuberculosis incidence
A. Time interval 
after ART start
Total number of hospital 
admissions per time 
interval
Children with hospital 
admissions per time 
interval, n (%) Most common reasons for admission
0 - <1 year 92 53 (41.7) LRTI (51%), GE (8%), LRTI and GE (8%), septicaemia (8%), 
PTB (5%)
≥1 - <5 years 67 43 (33.9) LRTI (40%), PTB (16%), GE (9%), septicaemia (6%)
≥5 - <10 years 42 24 (18.9) LRTI (45%), measles (19%), GE (7%)
≥10 - <15 years 20 14 (11.0) LRTI (40%), PTB (20%), appendicitis (10%), epilepsy (10%)
B. Time of TB diagnosis after 
ART start
Patients with TB 
diagnosis, n (%)
Patients not virally 
suppressed at TB 
diagnosis, n (%)
Patients with advanced or severe immune suppression  
at TB diagnosis, n (%)
On TB treatment at ART start 
or <4 weeks of ART start
15 (11.8) n/a 12 (80.0)
≥4 - ≤24 weeks 4 (3.1) n/a 4 (100)
>24 weeks - ≤1 year 5 (3.9) 2 (40.0) 3 (60.0)
>1 - ≤5 years 23 (18.1) 13 (56.6) 6 (26.1)
>5 - ≤10 years 12 (9.4) 8 (66.7) 2 (16.7) 
>10 years 9 (7.1) 4 (44.4) 4 (44.4)
ART = antiretroviral therapy; LRTI = lower respiratory tract infection; GE = gastroenteritis; PTB = pulmonary tuberculosis; TB = tuberculosis; n/a = not applicable.
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